Eric D Strobel

USPTO Granted Patents = 10 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 6.3

ph-index = 4

Forward Citations = 24(Granted Patents)

Location History:

Hatboro, PA (US) (2007 - 2010)
Warrington, PA (US) (2006 - 2018)

Company Filing History:

7 out of 2,078

Janssen Pharmaceutica Nv

patents

3 out of 86

Lexicon Pharmaceuticals, Inc.

patents

Years Active: 2006-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10106569 - Inhibitors of sodium glucose transporter 1 for constipation (2018-10-23),

2. 9688710 - Inhibitors of sodium glucose cotransporter 1 (2017-06-27),

3. 9200025 - Inhibitors of sodium glucose cotransporter 1 (2015-12-01),

4. 8633322 - Alkynyl derivatives useful as DPP-1 inhibitors (2014-01-21),

5. 8476302 - α-ketoamide derivatives useful endothelial lipase inhibitors (2013-07-02),

6. 7932261 - Macrocycle derivatives useful as inhibitors of β-secretase (BACE) (2011-04-26),

7. 7795440 - N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders (2010-09-14),

8. 7531545 - 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE) (2009-05-12),

9. 7196110 - N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders (2007-03-27),

10. 7091378 - Preparation of hydroxamic acids from esters in solution and on the solid phase (2006-08-15),

Title: **Eric D Strobel: A Leading Innovator in Pharmaceutical Patents**

Introduction

Eric D Strobel, based in Hatboro, PA, is a prominent inventor known for his significant contributions to the pharmaceutical field. With a total of 10 patents to his name, he has focused his research on innovative solutions for treating various diseases and disorders, particularly related to diabetes.

Latest Patents

Among his latest patents are the inventions related to inhibitors of sodium glucose transporter 1 (SGLT1). These patents describe compounds and compositions aimed at treating conditions such as constipation and diabetes. The specific formulas involve various substituents, addressing the need for effective therapeutic options for individuals suffering from these disorders.

Career Highlights

Eric has worked with several notable companies, including Janssen Pharmaceutica NV and Lexicon Pharmaceuticals, Inc. His work in these organizations has been instrumental in advancing pharmaceutical research and development. With a keen focus on SGLT1 inhibitors, Eric has made significant strides in creating targeted therapies that address critical health issues.

Collaborations

During his career, Eric has collaborated with several distinguished colleagues, including Chih Yung Ho and Yifang Huang. These partnerships have fostered an environment of innovation and shared expertise, contributing to the development of groundbreaking treatments in the field of diabetes and metabolic disorders.

Conclusion

Eric D Strobel's work has not only expanded the horizons of pharmaceutical science but has also played a crucial role in enhancing the quality of life for many patients. His innovative patents reflect his dedication to addressing complex health challenges and demonstrate the impact of collaboration in scientific advancements. With his continued efforts, Eric remains a vital figure in the realm of medical innovation.

This text is generated by artificial intelligence and may not be accurate.